For various ovarian endocrine disorders, such as polycystic ovary syndrome (PCOS), metformin, melatonin, and resveratrol have been used as targeted therapies, the underlying mechanisms of which are closely related to the expression of SIRT1, thus achieving significant therapeutic effects. Here, SIRT1 is linked to polycystic ovary syndrome.